Read Full Article 👇 👇

Read Full Article 👇 👇

An In-depth Analysis of Pfizer-BioNTech Covid-19 Vaccine Safety Report

An In-depth Analysis of Pfizer-BioNTech Covid-19 Vaccine Safety Report

An In-depth Analysis of Pfizer-BioNTech Covid-19 mRNA Vaccine's Safety Update Report

Part 1: Comparative Data Analysis

The first part of this analysis of the Periodic Safety Update Report 3 (PSUR 3) for the Pfizer-BioNTech Covid-19 mRNA vaccine, covering the six-month period from December 19, 2021, to June 18, 2022, focused on concerning pregnancy and lactation cases. The second part of the report delves into the tragic child deaths. A comparison of the data in PSUR 3 with the first PSUR reveals similar findings, with a significant 55% increase in case reports and a 36% increase in adverse events. The data shows that women reported three times as many cases as men, the most affected age group was 31-50 years old, one-third of all cases were classified as serious, and a high percentage of cases had outcomes classified as either unknown or not recovered.

Overview of the Data

The data shows 508,351 cases (individuals) suffering from 1,597,673 adverse events. Women reported three times the number of cases as men, one-third of all cases were classified as serious, and 3,280 deaths were reported. 60% of cases had either an unknown outcome or not recovered, and 92% of cases did not have any comorbidities. The highest number of cases occurred in the 31-50 year age group, and Germany had the highest recorded number of cases, accounting for 22.5% of all reported worldwide cases.

Germany's Case Reports

Germany recorded the highest number of cases, totaling 114,573, which accounted for 22.5% of all worldwide cases for that six-month period. Despite this, Germany’s Minister for Health, Karl Lauterbach, known for his pro-lockdown and pro-vaccine stance, claimed that the “vaccine was without side effects” in August 2021. However, a surprising U-turn was made in a TV interview where he acknowledged the heartbreaking cases of Covid-19 vaccine adverse effects. Recently, the first lawsuit against BioNTech was filed in Germany, with the plaintiff seeking damages due to an injury allegedly caused by the German vaccine manufacturer’s mRNA product.

Paediatric Cases

In the pharmacovigilance documents, PSUR 1 and 3, paediatric cases were identified as cases where the patient was aged 17 years or younger. The documents reveal that both Pfizer and BioNTech, along with the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), knew that the mRNA vaccine crossed the placenta and entered the breast milk from early 2021. The statement, 'paediatric cases involving exposure to the vaccine through trans-mammary or transplacentally route are excluded', serves as an admission of this fact and points to a grave abdication of responsibility in protecting infants and the unborn.

The 5–11-Year-Olds

In the post-marketing dataset, there were 9,605 individual cases reported in this age group, representing a significant 683% increase. The US had the highest number of reported cases, followed by Australia, the Philippines, and Germany. Approximately 17% of the total adverse event number of 22,457 were classified as serious. However, over 40% of all adverse events were classified as having an ‘unknown outcome’ and 14.5% as ‘not resolved.’ Disturbingly, there were 20 deaths recorded for this age group.

The 12-17-Year-Olds

There were 21,945 individual cases reporting 61,071 adverse events in this age group. Roughly one-third of all adverse events were classified as serious; another third as outcome ‘unknown’ and one-fifth as ‘not resolved.’ Tragically, 62 fatal cases were reported for this age group, roughly three times more than in the 5-11-year-old age group.

Conclusion

This analysis of the Pfizer-BioNTech Covid-19 mRNA vaccine's safety update report provides a sobering look at the adverse events and fatalities reported in relation to the vaccine, particularly among children and adolescents. The lack of investigation into these deaths is concerning, especially given the unusual nature of some of the fatal adverse events. This raises important questions about the safety and efficacy of the vaccine, particularly for younger age groups. What are your thoughts on this report? Do you think enough is being done to investigate these adverse events and deaths? Share this article with your friends and join the conversation. Sign up for the Daily Briefing, delivered every day at 6pm, to stay informed about this and other important topics.

Some articles will contain credit or partial credit to other authors even if we do not repost the article and are only inspired by the original content.

Some articles will contain credit or partial credit to other authors even if we do not repost the article and are only inspired by the original content.

Show All
Top Stories
Show All